CAJ | 학술논문

目的：研究肺癌患者化疗前后癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、鳞状上皮细胞癌抗原（SCC-Ag）和细胞角蛋白19的可溶性片段（CYFRS21-1）的表达及其临床意义。方法选取2010年3月至2014年3月我院收治的肺癌患者68例为研究组，选取同期肺部良性疾病患者68例为对照组，采用电化学发光法测量研究组化疗前后和对照组血清中CEA、NSE、SCC-Ag 和 CYFRA21-1的表达水平。结果化疗前，研究组 CEA为（13．21±0.72）μg／L，NSE为（14．57±0．19）μg／L，SCC-Ag为（2．73±0．01）μg／L，CYFRA21-1为（8．21±0．05）μg／L，显著高于对照组，且差异有统计学意义（t＝10．123，10．089，9．959，9．714，P＝0．021，0．024，0．027，0．028）；65例成功化疗者CEA为（9．34±0．32）μg／L，NSE为（9．87±0．23）μg／L，SCC-Ag 为（1．31±0．01）μg／L，CYFRA21-1为（4．07±0.02）μg／L，与化疗前比较差异有统计学意义（t＝9．892，10．121，8．972，9．716，P＝0．027，0．019，0．031，0．029）；3例化疗失败者4种标志物显著增高，与化疗前比较差异有统计学意义（t＝9．921，9．919，8．792，8．935，P＝0．023，0．024，0.026，0．031）。结论肺癌患者血清中的CEA、NSE、SCC-Ag和CYFRA21-1水平化疗成功后显著降低，化疗失败则会显著升高，可用于对化疗疗效进行评价。
목적：연구폐암환자화료전후암배항원（CEA）、신경원특이성희순화매（NSE）、린상상피세포암항원（SCC-Ag）화세포각단백19적가용성편단（CYFRS21-1）적표체급기림상의의。방법선취2010년3월지2014년3월아원수치적폐암환자68례위연구조，선취동기폐부량성질병환자68례위대조조，채용전화학발광법측량연구조화료전후화대조조혈청중CEA、NSE、SCC-Ag 화 CYFRA21-1적표체수평。결과화료전，연구조 CEA위（13．21±0.72）μg／L，NSE위（14．57±0．19）μg／L，SCC-Ag위（2．73±0．01）μg／L，CYFRA21-1위（8．21±0．05）μg／L，현저고우대조조，차차이유통계학의의（t＝10．123，10．089，9．959，9．714，P＝0．021，0．024，0．027，0．028）；65례성공화료자CEA위（9．34±0．32）μg／L，NSE위（9．87±0．23）μg／L，SCC-Ag 위（1．31±0．01）μg／L，CYFRA21-1위（4．07±0.02）μg／L，여화료전비교차이유통계학의의（t＝9．892，10．121，8．972，9．716，P＝0．027，0．019，0．031，0．029）；3례화료실패자4충표지물현저증고，여화료전비교차이유통계학의의（t＝9．921，9．919，8．792，8．935，P＝0．023，0．024，0.026，0．031）。결론폐암환자혈청중적CEA、NSE、SCC-Ag화CYFRA21-1수평화료성공후현저강저，화료실패칙회현저승고，가용우대화료료효진행평개。
Objective To investigate the expression and significance of carcinoembryonic antigen(CEA),neuron spe-cific enolase(NSE),squamous cell carcinoma antigen(SCC-Ag)and cytokeratin 19 soluble fragment(CYFRS21-1)before and after chemotherapy in patients with lung cancer.Methods 68 cases of patients with lung cancer in March 2010 to March 2014 in our hospital were selected,as the study group,another 68 cases of patients with benign pulmonary dis-ease were selected,as the control group,the serum levels of CEA,NSE,SCC-Ag and CYFRA2 1-1 of the study group and the control group were measured by the electrochemical luminescence before and after chemotherapy.Results CEA of the study group before chemotherapy was(13.21±0.72)μg/L,NSE was (14.57±0.19)μg/L,SCC-Ag was (2.73± 0.01)μg/L,CYFRA21-1 was (8.21±0.05)μg/L,significantly higher than the control group,with statistically signifi-cant difference (t=10.123,10.089,9.959,9.714,P=0.021,0.024,0.027,0.028);The CEA in 65 cases of patients with success chemotherapy was (9.34±0.32)μg/L,NSE was (9.87±0.23)μg/L,SCC-Ag was (1.31±0.01)μg/L, CYFRA21-1 was (4.07±0.02)μg/L,when compared with before treatment the differences were statistically signifi-cant (t=9.892,10.121,8.972,9.716,P=0.027,0.019,0.031,0.029);4 kinds of markers in 3 cases of patients with failure chemotherapy were significantly increased compared with before chemotherapy,the difference was statistically significant (t=9.921,9.919,8.792,8.935,P=0.023,0.024,0.026,0.031).Conclusion The serum CEA,NSE,SCC-Ag and CYFRA2 1-1 levels are significantly reduced after success of chemotherapy while they increase significantly after the failure of chemotherapy,which can make an evaluation for the chemotherapeutic effect.